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This paper describes methodological details used by WHO in 2015 to estimate TB                         
incidence, prevalence and mortality. Incidence and mortality are disaggregated by HIV                     
status, age and sex. Methods to derive MDR­TB burden indicators are detailed. Four                         
main methods were used to derive incidence: (​i) case notification data combined with                         
expert opinion about case detection gaps (120 countries representing 51% of global                       
incidence); (​ii​) results from national TB prevalence surveys (19 countries, 46% of global                         
incidence); (​iii​) notifications in high­income countries adjusted by a standard factor to                       
account for under­reporting and underdiagnosis (73 countries, 3% of global incidence)                     
and (​iv​) capture­recapture modelling (5 countries, 0.5% of global incidence). Prevalence                     
was obtained from results of national prevalence surveys in 21 countries, representing                       
69% of global prevalence). In other countries, prevalence was estimated from incidence                       
and disease duration. Mortality was obtained fromnational vital registration systems of                       






Global targets for reductions in TB disease burden by 2015 were set within the context                             
of the United Nations’ Millennium Development Goals (MDGs)​1​. The targets were that                       
TB incidence should be falling, and that TB mortality and prevalence rates should be                           
halved by 2015 compared with their level in 1990. Starting in 1997, global TB reports                             
were published annually by WHO, providing updated data on case notifications and                       
estimated TB burden. In June 2006, the WHO Task Force on TB Impact Measurement                           
was established​2​, with the aim of ensuring that WHO’s assessment of whether 2015                         
targets were achieved should be as rigorous, robust and consensus­based as possible.                       
The Task Force reviewed methods and provided recommendations in 2008, 2009 and                       
most recently in March 2015. Methods described in this paper reflect short­term                       
recommendations from the 2015 review. The final MDG assessment was published in                       
WHO’s 2015 global TB report​3​.  
Estimates of the burden of disease caused by TB and measured in terms of incidence,                             
prevalence and mortality are produced annually by WHO using information gathered                     
through surveillance systems (case notifications and death registrations), special studies                   
(including surveys of the prevalence of disease), mortality surveys, surveys of                     




Historically, a major source of data to derive incidence estimates were results from                         
tuberculin surveys conducted in children​4​. Early studies showed the following                   
relationship between the annual risk of infection denoted λ and the incidence of smear                           
positive TB denoted ​I​s+​: one smear positive case infects on average 10 individuals per                           
year for a period of 2 years and a risk of infection of 10​­2​y​­1 corresponds approximately to                                 
an incidence rate of 50 10​­5​y​­1​. ​However, this relationship no longer holds in the        ×                    
context of modern TB control and in HIV settings​5​. In addition to uncertainty about the                             
relationship between λ and​I​s+​, estimates of incidence obtained from tuberculin surveys                       
suffer from other sources of uncertainty and bias, including unpredictable diagnostic                     
performance of the tuberculin test​6​, digit preference when reading and recording the                       
size of tuberculin reactions​7​, sensitivity to assumptions about reaction sizes attributed to                       
infection​8​, sensitivity to the common assumption that the annual risk of infection is age                           
invariant, and lastly, sensitivity of overall TB incidence estimates to the assumed                       
proportion of TB incidence that is smear positive. 
A first global and systematic estimation exercise led by WHO in the early 1990s                           
estimated that there were approximately 8 million incident TB cases in 1990 (152                          ×
10​­5​y​­1​) and 2.6­2.9 million deaths (46­55 10​­5​y​­1​)​9​. A second major reassessment was          ×            
published in 1999​10​, with an estimated 8 million incident cases for the year 1997 (136                            ×
10​­5​y​­1​), and 1.9 million TB deaths (32 10​­5​y​­1​). The most important sources of            ×            
information were case notification data for which gaps in detection and reporting were                         




TB incidence has never been measured through population based surveys at national                       
level because this would require long­term studies among large cohorts of people                       
(hundreds of thousands), involving high costs and challenging logistics. Notifications of                     
TB cases provide a good proxy indication of TB incidence in countries that have both                             
high­performance surveillance systems (for example, there is little under­reporting of                   
diagnosed cases) andwhere the quality of and access to health caremeans that few cases                               
remain undiagnosed. In the large number of countries where these criteria are not yet                           
met, better estimates of TB incidence can be obtained from an inventory study. An                           
inventory study is a survey to quantify the level of under­reporting of detected TB cases;                             
if certain conditions aremet, capture­recapturemethods can also be used to estimate TB                           
incidence ​11​. 
The ultimate goal of TB surveillance is to directly measure TB incidence from national                           
case notifications in all countries. This requires a combination of strengthened                     
surveillance, better quantification of under­reporting (i.e. the number of newly                   
diagnosed cases that are missed by surveillance systems) and universal access to health                         
care (to minimize under­diagnosis of cases). A TB surveillance checklist developed by                       
the WHO Global Task Force on TB Impact Measurement defines the standards that                         
need to be met for notification data to provide a direct measure of TB incidence​12​. By                               
August 2015, a total of 38 countries including 16 high TB burden countries (HBCs) had                             
completed the checklist. 
Methods currently used by WHO to estimate TB incidence can be grouped into four                           
major categories. Figure 1 shows the distribution of countries according to the four                         
categories: 
1. Case notification data combined with expert opinion about case detection                   
gaps (120 countries); 
2. Results from national TB prevalence surveys (19 countries); 




Method 1 ­ Case notification data combined with expert opinion about case detection                         
gaps. 
Expert opinion, elicited in regional workshops, national consensus workshops or                   
country missions, is used to estimate levels of under­reporting and under­diagnosis.                     
Trends are estimated using either mortality data, national repeat surveys of the annual                         
risk of infection or exponential interpolation using estimates of case detection gaps for                         
three years. Thismethodwas used for 120 countries (Figure 1) that accounted for 51% of                               
the estimated global number of incident cases in 2014. The estimation of case detection                           




where ​I denotes incidence, ​N denotes case notifications, ​f denotes a cubic spline                         
function in countries with large year­to­year fluctuations in ​N​, or else, the identity                         
function. The incidence series are completed using assumptions about changes in CFR                       
over time in countries with evidence of improvements in TB prevention and care, such                           






A full description of the methods used in regional workshops where expert opinionwas                           
systematically elicited following an in­depth analysis of surveillance data is publicly                     
available in a report of the workshop held for countries in the African Region (inHarare,                               
Zimbabwe, December 2010)​13​. In some countries, case reporting coverage changed                   
significantly during the period 1990­2014 as a result of disease surveillance reforms (e.g.                         
disease surveillance was thoroughly reformed after the SARS epidemic in China, the                       
Ministry of Justice sector notified cases among prisoners in Russia starting in the early                           
2000s). Trends in incidence were derived from repeat tuberculin survey results in                       
Bhutan, India and Yemen and from trends in mortality in 40 countries (includingmost                           
countries in Eastern Europe).  
The proportion of cases that were not reported were assumed to follow a Beta                           







Time series for the period 1990–2014 were built according to the characteristics of the                           
levels of under­reporting and under­diagnosis that were estimated for the three                     
reference years. A cubic spline extrapolation of​V and​E​, with knots set at the reference                               
years, was used for countries with low­level or concentratedHIV epidemics. In countries                         
with a generalized HIV epidemic, the trajectory of incidence from 1990 to the first                           




where ​h is the prevalence of HIV in the general population,​ρ is the TB incidence rate                                 
ratio among HIV­positive individuals over HIV­negative individuals and ​ϑ is the                     
prevalence of HIV among new TB cases. 
If there were insufficient data to determine the factors leading to time­changes in case                           
notifications, incidence was assumed to follow a horizontal trend going through the                       
most recent estimate of incidence. 
Limitations of the method based on eliciting expert opinion about gaps in case detection                           
and reporting included a generally small number of interviewed experts; lack of clarity                         
about vested interests when eliciting expert opinion; lack of recognition of                     
over­reporting (due to over­diagnosis, e.g. in some countries of the former Soviet Union                         
implementing a large­scale systematic population screening policy that may result in                     
many people with abnormal chest X­ray but no bacteriological confirmation of TB                       
disease being notified and treated as new TB cases); incomplete data on laboratory                         
quality and high proportion of patients with no bacteriological confirmation of diagnosis                       
are a potential source of error in estimates. 
Method 2 ­ Results from national TB prevalence surveys. 
Incidence was estimated using prevalence survey results in 19 countries that accounted                       
for 46% of the estimated global number of incident cases in 2014. Two approaches were                             
used to derive incidence from prevalence. 
In a first approach, incidence is estimated usingmeasurements fromnational surveys of                         
the prevalence of TB disease combined with estimates of the duration of disease.                         
Incidence is estimated as the prevalence of TB divided by the average duration of                           
disease assuming epidemic equilibrium: let​N denote the size of a closed populationwith                           
the number of birth and deaths the same for a period Δ​t​>0, let ​C be the number of                                   
prevalent TB cases, ​P the prevalence rate so that​P​=​C​/​N​. Let​m denote the rate of exit                                 
from the pool of prevalent cases through mortality, spontaneous self­cure or cure from                         
treatment, and ​I the rate new cases are added to the pool. At equilibrium during the                               






In practice, the average duration of presence in the pool of prevalent cases cannot be                             
directly measured. For example, measurements of the duration of symptoms in                     
prevalent TB cases that are detected during a prevalence survey are systematically                       
biased towards lower values, since survey investigations truncate the natural history of                       
undiagnosed disease. Measurements of the duration of disease in notified cases ignore                       
the duration of disease among non­notified cases and are affected by recall biases. 
Literature reviews have provided estimates of duration of disease in untreated TB cases                         
from the pre­chemotherapy era (before the 1950s). The best estimate of the mean                         
duration of untreated disease (for smear­positive cases and smear­negative cases                   
combined) in HIV­negative individuals is about three years. There are few data on the                           
duration of disease in HIV­positive individuals. The assumed distributions of disease                     
durations are shown in Table 1. 
A second approach consists of estimating disease duration using three model                     
compartments: susceptibles (​S​), untreated TB (​U​) and treated TB (​T​). The size of​U and                             




Where ​I denotes Incidence, ​μ and ​θ denote mortality and self­cure or cure (with                           
subscripts ​u and ​t indicating untreated and treated cases), respectively, ​δ denotes the                         








is the proportion of incidence that dies or self­cures before treatment. π is assumed                           
distributed uniform with bounds 0 and 0.1. Table 2 shows estimates of incidence from                           
four recent prevalence surveys using this method. 
Among limitations of this method is the insufficient power of surveys to estimate the                           
number of prevalent TB cases on treatment with great precision. Further, in most                         
surveys, cases found on treatment during the survey do not have a bacteriological status                           
at onset of treatment documented based on the same criteria as survey cases                         
(particularly when culture is not performed routinely). The method, however, provides                     
more robust estimates of incidence compared with those obtained from expert opinion                       
(method 1). Figure 2 shows recent changes in estimates as new data became available.                           
As a result of recent survey data in Nigeria and Indonesia, global estimates of incidence                             
increased by about 1 million cases. Time trends, however, were not significantly                       
affected. 
In countries with high­level HIV epidemics that completed a prevalence survey, the                       
prevalence of HIV among prevalent TB cases was found systematically lower than the                         
prevalence of HIV among newly notified TB cases, with an HIV prevalence rate ratio                           
among prevalent TB over notified cases ranging from 0.07 in Rwanda (2012) to 0.5 in                             
Malawi (2013). The HIV rate ratio was predicted from a random­effects model fitting                         
data from 5 countries (Malawi, Rwanda, Tanzania, Uganda, Zambia) using a restricted                       
maximum likelihood estimator and setting HIV among notified cases as an effect                       
modifier​15​, using the R packagemetafor​16 (Figure 3). Themodel was then used to predict                             
HIV prevalence in prevalent cases from HIV prevalence in notified cases in African                         
countries that were not able to measure the prevalence of HIV among survey cases. 
The above two methods to derive incidence from prevalence are compared in Table 3. It                             
is not clear which method will perform better. The second method requires a sufficient                           
number of cases on treatment at the time of the survey (as a rule of thumb, at least 30                                     
cases) to generate stable estimates. When both methods can be applied (so far only in                             
low­HIV settings), results from two methods may be combined in a statistical ensemble                         
approach as follows: 
The incidence rate obtained using method​i is assumed distributed Beta with shape and                           








 Method 3 ­ Notifications in high­income countries adjusted by a standard factor to                         
account for under­reporting and under­diagnosis. 
This method is used for 73 high­income countries (Figure 1), which accounted for 3% of                             
the estimated global number of incident cases in 2014. 
TB surveillance systems from countries in the high­income group were assumed to                       
perform similarly well on average. The exceptions were the Republic of Korea, where the                           
under­reporting of TB cases has recently beenmeasured using annual inventory studies                       
and France, where the estimated level of under­reporting was communicated by public                       
health authorities, based on unpublished survey results. In the United Kingdom and the                         
Netherlands, incidence was obtained using capture­recapture modeling (see next                 
section). Surveillance data in this group of countries are usually internally consistent.                       
Consistency checks include detection of rapid fluctuations in the ratio of TB deaths / TB                             
notifications (​M​/​N​ ratio), which may be indicative of reporting problems. 
Method 4 ­ Capture­recapture modelling. 
This method was used for 5 countries: Egypt​17​, Iraq​18​, the Netherlands​19​, the United                         
Kingdom​20 and Yemen​21​. They accounted for 0.5% of the estimated global number of                         
incident cases in 2014. Capture­recapture modelling was considered in studies with at                       
least 3 lists and estimation of list dependencies​11​. The estimate of the surveillance gap in                             
the UK and the Netherlands was assumed time invariant. In Yemen, trends in incidence                           
were derived from results of two consecutive tuberculin surveys​22​. In Egypt and Iraq,                         
trends were derived using methods described in section describing method 1. 
HIV­positive TB incidence 
TB incidence was disaggregated by HIV and CD4 status using the Spectrum software​23​.                         
WHO estimates of TB incidence were used as inputs to the Spectrum HIV model. The                             
model was fitted toWHO estimates of TB incidence, and then used to produce estimates                             
of TB incidence among people living with HIV disaggregated by CD4 category​24​. A                         
regression method was used to estimate the relative risk (RR) for TB incidence                         
according to the CD4 categories used by Spectrum for national HIV projections​25​.                       
Spectrum data used the national projections prepared for the UNAIDS Report on the                         
global AIDS epidemic 2015. Themodel can also be used to estimate TBmortality among                             
HIV­positive people, the resource requirements associated with recently updated                 
guidance on ART and the impact of ART expansion. 
There is no satisfactory way to verify results for TB incidence among people living with                             
HIV when no HIV­testing data in TB are available. A comparative method to                         
disaggregate TB incidence by HIV is shown in annex 2. Provider­initiated testing and                         
counselling with at least 50%HIV testing coverage is themost widely available source of                             
information on the prevalence of HIV in TB patients. However, this source of data is                             




Estimates for men (males aged ≥15 years), women (females aged ≥15 years) and                         
children (aged <15 years) are derived as follows. Age and sex disaggregation of                         
smear­positive tuberculosis case notifications has been requested from countries since                   
the establishment of the data collection system in 1995, but with few countries actually                           
reporting these data to WHO. In 2006, the data collection system was revised to                           
additionally monitor age disaggregated notifications for smear­negative and               
extrapulmonary tuberculosis. The revision also included a further disaggregation of the                     
0–14 age group category to differentiate the very young (0–4) from the older children                           
(5–14). While reporting of age disaggregated data was limited in the early years of the                             
data collection system, reporting coverage kept improving. For 2012 case notifications,                     
age­specific data reached 99%, 83% and 83% of total smear­positive, smear­negative                     
and extrapulmonary tuberculosis global case notifications. Finally in 2013, another                   
revision of the recording and reporting system was necessary to allow for the capture of                             
cases diagnosed using WHO­approved rapid diagnostic tests (such as Xpert                   
MTB/RIF)​26​. This current revision requests the reporting of all new and relapse case                         
notifications by age and sex. The countries that reported age­disaggregated data in 2014                         
are shown in Figure 4. 
While there are some nationwide surveys that have quantified the amount of                       
under­reporting of cases diagnosed in the health sector outside the network of the                         
NTPs​17,19,27​, none have produced precise results by age. Small­scale, convenient­sampled                   
studies indicate that under­reporting of childhood tuberculosis can be very high​28,29 but                       
extrapolation to national and global levels is not yet possible. Plans for implementation                         
of nationwide surveys are under way in selected countries to measure under­reporting                       
of tuberculosis in children​30​. 
Results from two methods are combined to estimate TB incidence in children, using a                           
statistical ensemble approach based on equation 4. The first method estimates the                       
proportion of all TB cases that are in children as a function of expected age­specific                             
proportions of smear positive TB, according to a previously published approach​31                     
updated to incorporate recent data​32​. The second method is based on a dynamic model                           
that simulates the course of natural history of TB in children, starting from estimates of                             
tuberculous infection in children as a function of demographic and adult TB prevalence                         
and subsequently modelling progression to pulmonary and extra­pulmonary               
tuberculosis disease taking into account country­level BCG vaccination coverage and                   
HIV prevalence​33​.  
Using the sex disaggregated reporting of TB case notification data we calculated the                         
ratio of the number of TB cases notified in men compared with women as ameasure of                                 
the ratio ​r​1 for incident cases, assuming no sex differential in the detection of incident                             
cases. Evidence from prevalence surveys consistently show bigger recording and                   
detection gaps in men​34​. The assumption of no sex differential in the detection of                           
incident cases may thus lead to underestimating the proportion of men among incident                         
cases. With currently available data, it is not possible to estimate male and female case                             
detection ratios for all countries. 








Producing estimates of TB incidence among children is challenging primarily due to the                         





The best way to measure the prevalence of TB is through national population­based                         
surveys of TB disease​35,36​. Data from such surveys are available for an increasing number                           
of countries and were used for 21 countries (Figure 4), representing 69% of global                           
prevalence in 2014. Measurements of prevalence are typically confined to the adult                       
population, exclude extrapulmonary cases and do not allow the diagnosis of cases of                         
culture­negative pulmonary TB. 
TB prevalence all forms and all ages (​P​) is measured as: bacteriologically­confirmed                       
pulmonary TB prevalence (​P​p​) among those aged ≥15 measured from national survey                       






The estimate of overall prevalence ​P is affected by sampling uncertainty (relative                       
precision is typically about 20%), and uncertainty about ​e (of note, values for ​e vary                             
widely among countries with high­performance TB surveillance) and​P​c​. The quality of                       




Indirect estimates of prevalence were calculated by solving equation 3 for​P​, summing                         
over 4 case categories 
   
where the index variable​i denotes HIV+ and HIV–, the index variable​j denotes treated                             
and non­treated cases, and ​d​ denotes the duration of disease. 
When there is no direct measurement from a national survey of the prevalence of TB                             
disease, prevalence is the most uncertain of the three TB indicators used to measure                           
disease burden. This is because prevalence is the sum of products of two uncertain                           
quantities, incidence and disease duration. There is scarce empirical data on disease                       
duration (a typically large proportion of bacteriologically confirmed cases detected                   
during TB prevalence surveys did not report symptoms suggestive of TB at the time of                             
survey investigations​34​). Unless measurements were available from national               
programmes (for example, Turkey), assumptions of the duration of disease were used as                         




The best sources of data about deaths from TB (excluding TB deaths among                         
HIV­positive people) are vital registration (VR) systems in which causes of death are                         
coded according to ICD­10 (although the older ICD­9 and ICD­8 classification are still in                           
use in several countries), using ICD­10: A15­A19 codes, equivalent to ICD­9: 010­018.                       
When people with AIDS die from TB, HIV is registered as the underlying cause of death                               
and TB is recorded as a contributory cause. Since one third of countries with VR systems                               
report to WHO only the underlying causes of death and not contributory causes, VR                           
data usually cannot be used to estimate the number of TB deaths inHIV­positive people.                             
Two methods were used to estimate TB mortality among HIV­negative people: 
● direct measurements of mortality from VR systems or mortality surveys (129                     
countries, in green in Figure 6); 
● indirect estimates derived from multiplying estimates of TB incidence by                   
estimates of the CFR (88 countries). 
Estimating TB mortality among HIV­negative people from vital               
registration data and mortality surveys 
As of July 2015, 130 countries had reportedmortality data toWHO (including data from                             
sample VR systems and mortality surveys), including 10 of the 22 high TB burden                           
countries. The VR data on TB deaths from Zimbabwe were not used because large                           
numbers of HIV deaths were miscoded as TB deaths. Improved empirical adjustment                       
procedures for such miscoding have recently been published​37​. Estimates for South                     
Africa adjusted for HIV/TB miscoding were obtained from the Institute of Health                       
Metrics and Evaluation at ​http://vizhub.healthdata.org/cod/​. Results from mortality               
surveys were used to estimate TB mortality in India and Viet Nam as an interim                             
measure. 
Among the countries for which VR data could be used (Figure 5), there were 2361                             
country­year data points 1990–2014, after 13 outlier data points from systemswith very                         
low coverage (<20%) as estimated by WHO​38 or very high proportion of ill­defined                         
causes (>50%) were excluded for analytical purposes. The median number of data                       
points per country was 21 (Interquartile range 15 ­ 23). 
Reports of TB mortality were adjusted upwards to account for incomplete coverage                       
(estimated deaths with no cause documented) and ill­defined causes of death (ICD­9:                       
B46, ICD­10: R00–R99)​38​. It was assumed that the proportion of TB deaths among                         
deaths not recorded by the VR system was the same as the proportion of TB deaths in                                 
VR­recorded deaths. For VR­recorded deaths with ill­defined causes, it was assumed                     
that the proportion of deaths attributable to TB was the same as the observed                           




where ​v denotes coverage (i.e. the number of deaths with a documented cause divided                           




The uncertainty calculation does not account for miscoding, such as HIV deaths                       
miscoded as deaths due to TB, except in South Africa. 
Missing data between existing adjusted data points were interpolated. Trailing missing                     
values were predicted using exponential smoothingmodels for time series​39​. A penalized                       
likelihood method based on the in­sample fit was used for country­specific model                       
selection. Leading missing values were similarly predicted backwards to 1990. 
In 2014, 43% of global TB mortality (excluding HIV) was directlymeasured fromVR or                             
survey data (or imputed from survey or VR data from previous years). The remaining                           
57% was estimated using the indirect methods described in the next section. 
 
Estimating TB mortality among HIV­negative people from             
estimates of case fatality rates and TB incidence 
In 88 countries lacking VR data of the necessary coverage and quality, TBmortality was                             
estimated as the product of TB incidence and the case fatality rate (CFR) after                           
disaggregation by case type as shown in Table 4, following a literature review of CFRs by                               
the TB Modelling and Analysis Consortium (TB­MAC): 
  (5) 
where ​M denotes mortality, ​I incidence. ​fu and ​ft denote CFRs untreated and treated,                           
respectively and the superscript denotesHIV status.​T denotes the number of treated TB                           
cases. In countries where the number of treated patients that are not notified                         
(under­reporting) is known from an inventory study, the number of notified cases is                         
adjusted upwards to estimate ​T​­​ accounting for under­reporting. 
Figure 7 shows a comparison of 129 VR­basedmortality estimates for 2014 and indirect                           
estimates obtained from the CFR approach for the same countries. Of note, countries                         
with VR data tend to be of a higher socio­economic status comparedwith countries with                             
no VR data where the indirect approach was used. 
Estimating TB mortality among HIV­positive people 
TB mortality among HIV­positive is calculated using equation 5, exchanging                   
superscripts ­ with +. The case fatality ratios were obtained in collaborationwith the TB                             
Modeling and Analysis Consortium (TB­MAC), and are shown in Table 5. The                       
disaggregation of incident TB into treated and not treated cases is based on the ratio of                               
the point estimates for incident and notified cases, adjusted for under­reporting. A                       
single CFR was used for all bootstrapped mortality estimates​24​.  
Direct measurements of HIV­associated TB mortality are urgently needed. This is                     
especially the case for countries such as South Africa and Zimbabwe, where national VR                           
systems are already in place. In other countries, more efforts are required to initiate the                             
implementation of sample VR systems as an interim measure. 
Disaggregation of TB mortality by age and sex 
From the age­specific adjusted (for coverage and ill­defined causes) number of deaths                       
from VR, we first estimate the ratio ​r​2 of rates in children (​M​0−14​) compared to adults                               
(​M​15+​) (equation 7). The estimation of ​r​2 is based on a chained equations multiple                           
imputation approach. The imputation model covariates include total notifications,                 
population proportion aged more than 65 years, an indicator variable for the                       
epidemiological region and whether a country was one of the 22 HBCs​3​. The overall                           
mortality rate for all ages (​M​) can be expressed as a weighted average of mortality in                               







In countries with VR or mortality survey data, ​M​0−14 is directly measured. For the sex                             
disaggregation of TB mortality among adults (​M​15+​), sex­specific adjusted (for coverage                     
and ill­defined causes) number of deaths fromVR to estimatemortality rates inmen​M​m                             
and women ​M​w were used. The ratio of these rates ​r​3​=​M​m​/​M​w is either directly                           
measured in countries with VR data or imputed in countries without and sex­specific                         
mortality rates are then derived in a manner similar to shown in equation 6. 
TB deaths among HIV­positive people were disaggregated by age and sex using the                         





Projections of incidence, prevalence and mortality up to 2015 enable assessment of                       
whether global targets set for 2015 are likely to be achieved at global, regional and                             
country levels. Projections for the year 2015 were made using exponential smoothing                       
models fitted to data from 2007–2014, based on an algorithm that selects the best                           
among models within a family of exponential smoothing models, using a penalized                       
likelihood method as a selection criterion​40​. Point forecasts are computed using the best                         




There are many potential sources of uncertainty associated with estimates of TB                       
incidence, prevalence and mortality, as well as estimates of the burden of                       
HIV­associated TB and MDR­TB. These include uncertainties in input data, in                     
parameter values, in extrapolations used to impute missing data, and in the models                         
used. Uncertainty in population estimates was not accounted for.  
Notification data are of uneven quality. Cases may be under­reported (for example,                       
missing quarterly reports from remote administrative areas are not uncommon),                   
misclassified (in particular, misclassification of recurrent cases in the category of new                       
cases is common), or over­reported as a result of duplicated entries in TB information                           
systems. The latter two issues can only be addressed efficiently in countries with                         
case­based nationwide TB databases that include patient identifiers. Sudden changes in                     
notifications over time are often the result of errors or inconsistencies in reporting. 
Uncertainty bounds and ranges were defined as the 2.5th and 97.5th centiles of outcome                           
distributions. The general approach to uncertainty analyses was to draw values from                       
specified distributions in Monte Carlo simulations or else, uncertainty was propagated                     
analytically by approximating the mean and the second central moment of functions of                         
random variables using higher­order Taylor series expansion​41 in a matrix based                     
approach​42​.  
Conclusion 
The measurement methods described here can be combined to assess tuberculosis                     
incidence, prevalence and mortality, to evaluate progress towards targets for                   
tuberculosis control and the level of achievement of the MDGs for TB. Alternative TB                           
burden estimation methods have been developed by the Institute of HealthMetrics and                         
Evaluation​43​, with generally consistent results at the global level compared with WHO,                       
but with marked differences in specific countries. Discrepancies in estimates from                     
different agencies reflect the questionable quality and completeness of the underlying                     
data. Further convergence in estimates will result from improvements inmeasurements                     
at country level. National control programmes should be able to measure the level and                           
time trends in incidence through well­performing TB surveillance with universal access                     
to health. In countries with incomplete routine surveillance, prevalence surveys of TB                       
disease provide estimates of TB burden that do not heavily rely on expert opinion. The                             
performance of TB surveillance should be assessed periodically​12 and the level of                       
under­reporting should be measured​11 and minimized. Tuberculosis mortality will                 
ideally be measured by counting deaths in a comprehensive vital registration system​38​.  
The challenge presented by assessing MDGs achievements has been to measure trends                       
in TB incidence, prevalence, and deaths. The MDGs have now been followed by a set of                               
17 Sustainable Development Goals (SDGs) with an end date of 2030. A target within the                             
health­related SDG is to “End the epidemics of AIDS, TB,malaria and neglected tropical                           
diseases, and combat hepatitis, water­borne diseases and other communicable                 
diseases”. WHO’s post­2015 global TB strategy, known as the End TB Strategy​44​, also                         
has the goal of ending the global TB epidemic, with corresponding targets of a 90%                             
reduction in TB deaths and an 80% reduction in the TB incidence rate by 2030.                             
Improved measurements through substantial investments in health information               
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Incidence is defined as the number of new and recurrent (relapse) episodes of TB (all                             
forms) occurring in a given year. Recurrent episodes are defined as a new episode of TB                               
in people who have had TB in the past and for whom there was bacteriological                             
confirmation of cure and/or documentation that treatment was completed. 
Prevalence​ is defined as the number of TB cases (all forms) at a the middle of the year. 
Mortality from TB is defined as the number of deaths caused by TB in HIV­negative                             
people occurring in a given year, according to the latest revision of the International                           
classification of diseases (ICD­10). TB deaths among HIV­positive people are classified                     
as HIV deaths in ICD­10. For this reason, estimates of deaths from TB in HIV­positive                             
people are presented separately from those in HIV­negative people. 
The ​case fatality rate is the risk of death from TB among people with active TB                               
disease. 
The ​case notification rate refers to new and recurrent episodes of TB notified for a                             
given year. Patients reported in the ​unknown history category are considered incident                       
TB episodes (new or recurrent). 
Population estimates were the 2015 revision of the World Population Prospects,                     
which is produced by the United Nations Population Division (UNPD,                   




Annex 2 ­ Relationship between HIV prevalence in new TB cases                     
and HIV prevalence in the general population 
Let ​I and​N denote incident cases and the total population, respectively, superscripts +                           
and ­ denote HIV status, ​ϑ is the prevalence of HIV among new TB cases, ​h is the                                   

























1. Estimating overall TB incidence after review and cleaning of case notification                     
data; 
2. cleaning and adjusting raw mortality data from VR systems and mortality                     
surveys, followed by imputation of missing values in countries with VR or                       
survey data – in some countries, step 1 was updated to account for mortality                           
data; 
3. cleaning of measurements of HIV prevalence among TB patients followed by                     
estimating HIV­positive TB incidence using the Spectrum programme and                 
HIV­positive TB mortality; 
4. estimating HIV­negative TB mortality in countries with no VR data followed                     
with an update of step 1 in some countries; 
5. reviewing prevalence measurements, adjusting for childhood TB and               
bacteriologically unconfirmed TB, and estimating prevalence followedwith an                 
update of step 1 in some countries; 




























Cambodia 2002  260  42  12 (10­15)  2.9 (1.9­4)  4 (2.5­5.8) 
Cambodia 2011  205  80  8.3 (7.1­9.8)  1.2 (0.8­1.6)  6.7 (4.5­9.3) 
Myanmar 2009  300  79  6.1 (5­7.5)  1.8 (1.1­1.6)  3.3 (2­4.8) 
Thailand 2012  136  60  2.5 (1.9­3.5)  1.1 (0.5­1.6)  2.3 (1­3.5) 
 
 








Cambodia 2002  12 (10­15)  4 (2.5­5.8)  2.2 (1.5­2.9) 
Cambodia 2011  8.3 (7.1­9.8)  6.7 (4.5­9.3)  3.8 (2.2­5.8) 
Myanmar 2009  6.1 (5­7.5)  3.3 (2­4.8)  3.5 (2­5.1) 
















off  off  0.78 (0.65­0.94)  45 
off  on  0.09 (0.03­0.15)    ​47,48 
< 1 year  off  0.62 (0.39­0.86)  Data from review + assumptions 
< 1 year  on  0.06 (0.01­0.13)  Data from review + assumptions 
≥ 1 year  off  0.49 (0.31­0.70)  Assumptions 







Fig. 1 Main method to estimate TB incidence. In the first method, case notification data are                               
combined with expert opinion about case detection gaps (under­reporting and under­diagnosis),                     
and trends are estimated using either mortality data, repeat surveys of the annual risk of infection                               
or exponential interpolation using estimates of case detection gaps for three years. For all                           
high­income countries except the Netherlands and the United Kingdom, notifications are                     






Fig 2. ​Estimates of TB incidence obtained indirectly (in blue) based on case notifications and                             
expert opinion about detection and reporting gaps prior to a recent national prevalence survey,                           
and derived from prevalence using survey results (in red), corresponding to the survey year                           
(2012­2014). The length of segments indicate uncertainty ranges. Countries are presented in the                         
order of the difference between estimates, grouped by continent. Estimates derived from                       
prevalence are more robust. Post­survey estimates resulted in significant increases in estimated                       
incidence in Nigeria and Indonesia, two countries with large population sizes resulting in a                           
notable impact on global estimates. The often narrow uncertainty ranges of pre­survey estimates                         
reflect a certain level of overconfidence of experts asked to estimate plausibility ranges for                           




Fig. 3 HIV prevalence rate ratio among prevalent TB cases over notified TB cases in 5 countries                                 
(points with area proportional to inverse variance) against HIV prevalence in notified cases.                         










Fig. 5 Countries for which prevalence is estimated from prevalence survey measurements                       
(​n​=21). In the case of India, data from subnational surveys were pooled to provide a national                               
estimate. 
 






Fig. 7 Comparison of VR mortality (HIV­negative), horizontal axis (log scale) and mortality                         
predicted as the product of incidence and CFR, vertical axis (log scale). Horizontal and vertical                             
segments indicate uncertainty intervals. The dashed red line shows equality. The blue line and                           
associated grey banner show the least­squared best fit to the data, with a slope not constrained to                                 
one. 
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